Vical blames credit crunch for job cuts
This article was originally published in Scrip
Executive Summary
Vical, a US-based biopharmaceutical company, is to cut its staff by 20%, leaving around 120 employees working for the company. It expects the cost-reduction initiative, which also involves the accelerated closure of a research facility, to reduce future net losses and cash burn by around $4 million annually. In the current economic climate, Vectura needs to reduce spending and focus its efforts on advancing its two late-stage product development programmes, Vijay Samant, the company's president and CEO, said. Allovectin-7, an immunotherapeutic, is currently in a Phase III trial in patients with advanced, metastatic melanoma and a DNA vaccine for cytomegalovirus is currently in Phase II trials in stem cell transplant recipients. Vectura expects to incur restructuring charges of around $800,000 in the fourth quarter of this year and an additional $500,000 in the first quarter of next year related to the facility's closure.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.